Perfil de síntomas del tracto urinario inferior en el varón y su impacto en la calidad de vida

Cambronero, J.; Arlandis, Salvador; Errando, Carlos; Mora, A.

doi:10.1016/j.acuro.2012.11.011

Cited by 14 publications

(4 citation statements)

References 25 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The differences in cost persisted despite the greater cost for combined treatment. In our opinion, this reduction in unit costs is important from the standpoint of efficiency in the clinical management of this group of patients, especially considering the high percentage of patients with mixed clinical symptoms with a predominance of the storage component [ 2 ]. In a meta-analysis by Xin and coworkers [ 26 ], based on 15 clinical trials ( N = 4556), combination therapy (AAB and AM) improved LUTS with a low incidence of adverse effects.…”

Section: Discussionmentioning

confidence: 99%

“…This change of perspective, acknowledging the multifactorial etiology of male LUTS, and accepting that not all of the symptoms are necessarily related to the prostate, is mirrored in the current guidelines of Scientific Societies [ 1 , 3 , 5 – 7 ]. The main treatment objectives are to reduce symptoms, improve quality of life and prevent the development of complications [ 1 , 2 , 7 – 10 ]. In this regard, and as a step prior to treatment selection, the severity of symptoms should be assessed with the International Prostate Symptom Score (IPSS) [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia

Sicras‐Mainar¹,

Navarro‐Artieda²,

Mora³

et al. 2017

BMC Urol

View full text Add to dashboard Cite

BackgroundThere has been a change in the focus of attention from prostate to bladder, as the etiology of lower urinary tract symptoms (LUTS) makes the bladder an additional therapeutic target. This study aims to evaluate the use of resources and costs associated with the addition of an antimuscarinic (AM) in patients receiving an alpha-adrenergic-blocker (AAB) for the treatment of LUTS linked to benign prostatic hyperplasia (BPH).MethodsA multicentre, retrospective study was conducted using patient records from the databases of six primary care centers in Spain. Men with moderate-to-severe LUTS (IPSS > 7) who were initiated on AM treatment between January 2010 and December 2012 without previous treatment with an AM or 5-alpha reductase inhibitor (5-ARI) and had been on treatment with an AAB for a minimum of 6 months prior to the addition of the AM with a minimum of two records in the database were included. Comorbidity, treatment persistence, and use of resources and costs (direct and indirect) during monotherapy (AAB alone) and following the introduction of combination therapy (AAB + AM) over a treatment period of up to a year were compared. A paired sample Student t-test was performed where p < 0.05 were considered significant.ResultsOne hundred and ninety-one patients (mean age (SD): 70 (10.4) years) were treated with combination therapy. Treatment persistence on combination therapy after 12 months was 65.4% (95% CI: 58.8-72.2%). Use of resources was numerically lower after initiation of combination therapy vs pre-treatment (AAB alone) period for medical visits (/year/patient) (13.4 (4.6) vs 15.4 (4.4) p < 0.010), percentage of patients using concomitant medication (13.3% vs 19.1%) and use of pads (9.7% vs 13.4%) among others analyzed. Comparing AAB vs AAB + AM, there were a numeric reduction in total cost/year (€2399 vs €2011; p = 0.135) and a reduction of costs due to medical visits (€645 vs. €546; p = 0.003) and concomitant medication (€181 vs. €101; p = 0.009).ConclusionsThe addition of an AM agent in patients treated for LUTS with AAB is associated with a lower use of healthcare resources in terms of number of medical visits, and concomitant medications required, thereby leading to reduction of overall costs to the healthcare system.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia

Sicras‐Mainar¹,

Navarro‐Artieda²,

Mora³

et al. 2017

BMC Urol

View full text Add to dashboard Cite

show abstract

“…Por otro lado, el envejecimiento progresivo de la población y el reconocimiento relativamente reciente de los síntomas del tracto urinario inferior (STUI) de llenado en el varón también como VH7, 8, 9 hacen necesario llevar a cabo nuevos estudios poblacionales de base clínica para conocer mejor la prevalencia actual de la VH. Asimismo, aunque sabemos que este proceso puede implicar un severo impacto sobre la calidad de vida de los pacientes y en ocasiones también en la productividad laboral10, 11, realmente desconocemos el impacto que los síntomas de VH causan desde una perspectiva psicológica y social en nuestro entorno.…”

Section: Introductionunclassified

Prevalencia y caracterización de la vejiga hiperactiva detectada en una población de Madrid con el cuestionario OAB-V3 autoadministrado en atención primaria

Angulo¹,

Calderín²,

Fernández³

et al. 2018

Atención Primaria

View full text Add to dashboard Cite

show abstract

“…The condition manifests as lower urinary tract symptoms (LUTS). It significantly disrupts and compromise voiding function with decreases quality of life [2]. In majority of cases early detection with appropriate treatment, can lead to decreased complications [3].…”

Section: Introductionmentioning

confidence: 99%

2013 Annual National Digital Rectal Exam Day: impact on prostate health awareness and disease detection

Chua

Lapitan

Morales

et al. 2014

Prostate International

View full text Add to dashboard Cite

Purpose:“Mag-paDRE” is a yearly prostate health public awareness program initiated by the Philippine Urological Association. This study aimed to describe the demographic and clinical data of the participants in the 2013 “Mag-paDRE” program and to identify factors that will further improve prostate health public awareness.Methods:A descriptive cross-sectional study undertaken to collect and assess the demographic data, International Prostate Symptom Score (IPSS) and digital rectal examination findings of the participants in the “Mag-paDRE” conducted in the 10 Philippine Board of Urology (PBU) different accredited training institutions. Descriptive statistics was used to report the proportion of Filipino men aged 40 or older who presented for their first prostate health evaluation. Clinical profile were reviewed and summarized. The study protocol was registered in the Clinicaltrial.gov under Identifier NCT01886547.Results:A total of 925 participants from the 10 PBU accredited training institutions were assessed. Among the 10 training institutions the large tertiary government owned medical center had the highest number of participants and target participants recruited; while the private sectors owned tertiary hospitals have the highest proportion of target participants and cases. According to the predetermined definition of this study, 614 (66%) were considered the target population for the “Mag-paDRE” program. The mean age of the target participants was 58.9±9.9. Only 360 of 614 (59%) were new case, 118 (32.7%) had severe lower urinary tract symptoms (LUTS), 223 (62%) had moderate LUTS, 19 (5.3%) were asymptomatic but with hard prostates, palpable prostate nodules or prostate tenderness. The most bothersome symptoms were incomplete bladder emptying (30.2%), and frequency (22.9%).Conclusions:Overall, the 2013 “Mag-paDRE” among the 10 training institutions was effective in promoting prostate health awareness. A need to modify the preactivity information dissemination by these institutions can be done to further increase the attendance of targeted population of the prostate health awareness program.

show abstract

Perfil de síntomas del tracto urinario inferior en el varón y su impacto en la calidad de vida

Cited by 14 publications

References 25 publications

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia

Prevalencia y caracterización de la vejiga hiperactiva detectada en una población de Madrid con el cuestionario OAB-V3 autoadministrado en atención primaria

2013 Annual National Digital Rectal Exam Day: impact on prostate health awareness and disease detection

Contact Info

Product

Resources

About